SGHT at a glance
Sight Sciences, Inc. (SGHT, SEC CIK 1531177) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Sight Sciences, Inc. (SGHT) reported revenue of $77.4 million (down 3.1% from FY2024) and a net loss of $38.4 million. Diluted EPS was -$0.74.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Sight Sciences, Inc. (SGHT) shares worth $45.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bauerlein Alison on October 2, 2026 of 25,260 shares at $8.85 per share.
- In the last 90 days, SGHT insiders reported 0 open-market purchases ($0) and 5 open-market sales ($653K) on Form 4, a net sale of $653K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $77.4M
- −3.1% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$653K
- 13F holders
- 24 funds
- $45.7M · −1 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Risk-factor changes: No substantive Risk Factors text provided beyond 10-K cross-reference
- Reimbursement risk: Interventional Glaucoma coverage protection and broader Dry Eye reimbursement remain uncertain
- Regulatory risk: Extensive government regulation could affect product commercialization and operations
- Market risk: Competition from existing competitors and new entrants could hinder customer expansion
- Financial risk: Secured credit facility payment-term compliance remains a stated uncertainty
AI summary of the SGHT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Kashif Rashid appointed Chief Legal Officer and Corporate Secretary effective August 10, 2026
- $450,000 base salary and 50% target annual cash bonus
Item EX-99.1: Item EX-99.1
- Q2 revenue $23.4M, up 20% YoY; glaucoma revenue rose 8% while dry-eye revenue surged 704% to $2.7M
- Gross margin reached 91.4%, with dry-eye margin improving to 84.7% from 38.4% YoY
Item 7.01: Regulation FD Disclosure
- Investor presentation posted August 5, 2026 under Regulation FD
- Exhibit 99.2 contains materials management expects to use with investors and analysts
Item 2.02: Results of Operations and Financial Condition
- Filing contains only signature certification, with no operating results or financial figures disclosed
- Signed August 5, 2026 by James Rodberg, Chief Financial and Accounting Officer
Item 5.07: Submission of Matters to a Vote of Security Holders
- 76.2% turnout, with 41,456,258 shares represented at the annual meeting
- Gerhard Burbach and Staffan Encrantz reelected as Class II directors through 2029
AI summaries of SGHT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SGHT
Don't miss the next SGHT filing
- Alerts as it files. A push when SGHT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SGHT, by share count.
- Ask anything. An AI agent that reads every SGHT filing and answers with sources.
SGHT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bauerlein Alison | Sell | Oct 2, 2026 | 25,260 | $8.85 |
| Taylor Brenton | Sell | Oct 2, 2026 | 2,988 | $8.85 |
| Rodberg James | Sell | Oct 2, 2026 | 7,208 | $8.85 |
| Badawi Paul | Sell | Oct 1, 2026 | 29,653 | $9.05 |
| Badawi David | Sell | Oct 1, 2026 | 7,797 | $9.05 |
| Rashid Kashif | A | Aug 10, 2026 | 181,818 | - |
| HAYDEN JEREMY B. | Sell | Jul 6, 2026 | 12,733 | $5.51 |
| Badawi David | Sell | Jul 6, 2026 | 7,418 | $5.51 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $79.9M | $77.4M |
| Gross Profit | - | $68.3M | $66.7M |
| Operating Income | - | -$50.5M | -$37.1M |
| Net Income | - | -$51.5M | -$38.4M |
| Gross Margin | - | 85.5% | 86.2% |
| Op. Margin | - | -63.3% | -48.0% |
| Net Margin | - | -64.5% | -49.7% |
| Balance Sheet | |||
| Total Assets | $166.7M | $142.8M | $115.3M |
| Equity | $120.2M | $87.5M | $63.9M |
| ROE | - | -58.8% | -60.1% |
| Per Share | |||
| EPS | - | $-1.03 | $-0.74 |
| Cash Flow | |||
| Operating CF | - | -$22.4M | -$29.7M |
| CapEx | - | $385K | $224K |
Source: XBRL data in Sight Sciences, Inc. (SGHT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SGHT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $45.7M |
| Q1 2026 | 25 | $30.1M |
| Q4 2025 | 23 | $66.7M |
| Q3 2025 | 20 | $25.6M |
| Q2 2025 | 20 | $30.5M |
| Q1 2025 | 17 | $13.8M |
| Q4 2024 | 12 | $15.3M |
| Q3 2024 | 10 | $11.0M |
- AQR Capital Management+259.0K (+187%)
- BlackRock+251.2K (+9%)
- Vanguard Capital Management LLC+121.1K (+8%)
- Citadel Advisors LLC+81.0K (+60%)
- Goldman Sachs Group+73.7K (+58%)
- Millennium Management−184.7K (-71%)
- Two Sigma Investments−86.2K (-68%)
- Renaissance Technologies LLC−80.7K (-28%)
- D.E. Shaw & Co−31.4K (-10%)
- Morgan Stanley−29.9K (-16%)
- Prudential Financial−56.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 151 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SGHT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 23, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SGHT SEC filings: frequently asked questions
Are SGHT insiders buying or selling?
In the last 90 days, Sight Sciences, Inc. (SGHT) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $652,777 by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SGHT stock?
As of June 30, 2026, the largest Sight Sciences, Inc. (SGHT) holders among the 13F filers tracked by SignalX were BlackRock ($16.7 million), Vanguard Capital Management LLC ($8.5 million), State Street Corp ($4.5 million), AQR Capital Management ($2.2 million), Dimensional Fund Advisors ($2.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SGHT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Sight Sciences, Inc. (SGHT) reported revenue of $77.4 million (down 3.1% from FY2024) and a net loss of $38.4 million. Diluted EPS was -$0.74. The figures come from the XBRL data in the 10-K.
What did SGHT report in its latest 8-K?
Sight Sciences, Inc. (SGHT) filed an 8-K on August 10, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Kashif Rashid appointed Chief Legal Officer and Corporate Secretary effective August 10, 2026.
What are the latest SGHT SEC filings?
Sight Sciences, Inc. (SGHT) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on October 5, 2026.
What is SGHT's SEC CIK number?
Sight Sciences, Inc. (SGHT)'s SEC Central Index Key (CIK) is 1531177. EDGAR lists every SGHT filing under that number.
Ask anything about SGHT
The research agent reads SGHT's filings, financials, insider trades and 13F holders, then answers with sources.